Status:
COMPLETED
First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia
Lead Sponsor:
AstraZeneca
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare gefitinib with carboplatin / paclitaxel doublet chemotherapy given as first line treatment in terms of progression free survival in selected NSCLC patients with...
Eligibility Criteria
Inclusion
- Locally advanced Stage IIIB not amenable to local therapy or Stage IV (metastatic) NSCLC with adenocarcinoma histology.
- Never smokers or light ex-smokers.(ceased smoking at least 15 years before Day 1 of study treatment and 10 pack-years or fewer)
Exclusion
- Had prior chemotherapy, biological (including targeted therapies such as EGFR and vascular epidermal growth factor (VEGF) inhibitors) or immunological therapy.
- Pre-existing idiopathic pulmonary fibrosis evidence by CT scan at baseline.
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
1329 Patients enrolled
Trial Details
Trial ID
NCT00322452
Start Date
March 1 2006
End Date
June 1 2010
Last Update
November 7 2013
Active Locations (56)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Fuzhou, Fujian, China
2
Research Site
Guangzhou, Guangdong, China
3
Research Site
Wuhan, Hubei, China
4
Research Site
Nanjing, Jiangsu, China